Results 221 to 230 of about 71,564 (304)

eGFR slope as predictor of mortality in heart failure patients

ESC Heart Failure, Volume 12, Issue 2, Page 1217-1226, April 2025.
Abstract Aims Heart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real‐world HF patients, assessing eGFR trajectories and ...
Sofie Verstreken, Monika Beles, Clara L. Oeste, Ana Moya, Imke Masuy, Riet Dierckx, Ward Heggermont, Jeroen Dauw, Dries Hens, Jozef Bartunek, Marc Vanderheyden   +10 more
wiley   +1 more source

Rational and design of the digital diagnosis of cardiac sounds in paediatric patients (DI_SOUND) study. [PDF]

Eur Heart J Digit Health
Egidy Assenza G, Colombo A, Mastromarino V, D'Aversa A, Bartolacelli Y, Bonetti S, Calcagni G, Corvaglia L, Di Ienno L, Donti A, Fierro MF, Matteucci M, Marzullo R, Putotto C, Russo MG, Simonazzi G, Bego S, Versacci P, de Bodonia BMT.   +18 more
europepmc   +1 more source

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source

Evaluation and Treatment of Myocardial Bridging by Clinical Phenotype. [PDF]

J Soc Cardiovasc Angiogr Interv
Uretsky BF, Aleksandric SB, Vallurupalli S, Chaus A, Hakeem A, Blankenship JC, Birnbaum Y, Kern MJ.   +7 more
europepmc   +1 more source

Valve Migration After EVOQUE in Annuloplasty Band Rescued With SAPIEN-in-EVOQUE Strategy. [PDF]

Struct Heart
Lee B, Rahim MA, Specter M, Wojewoda O, Goldschmidt H, Chang E, Rahim H, Litwok Y, Kunnirickal S, Kim F, Grau J, Tayal R.   +11 more
europepmc   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Development of a Preoperative Transthoracic Echocardiography-Based Nomogram for Predicting 1-Year Cardiovascular Events in End-Stage Renal Disease Kidney Transplant Recipients. [PDF]

Echocardiography
Pan M, Xu L, Cai Y, Li Y, Deng W, Ou A, Gan S, Zhou Y, Wu J.   +8 more
europepmc   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Paradoxical improvement of mitral regurgitation associated with hyperadrenocorticism-related cardiac hypertrophy in a dog with myxomatous mitral valve disease. [PDF]

Vet Res Commun
Nam HS, Oh Y.
europepmc   +1 more source